Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (Paris:NANO) (NASDAQ:NBTX) announced a collaboration through its subsidiary Curadigm to advance gene therapy development using its proprietary Nanoprimer technology. The one-year agreement with a pharmaceutical company aims to improve treatment outcomes by enhancing the bioavailability of therapeutics and minimizing hepatic toxicity. The Nanoprimer technology helps prevent rapid clearance in the liver, allowing more drugs to accumulate in target tissues. This partnership is expected to foster new opportunities, particularly with RNA-based therapies, bolstering Curadigm's pipeline.
NANOBIOTIX (NASDAQ:NBTX, Euronext:NANO) has announced positive results from the phase Ib part of a phase Ib/II study evaluating NBTXR3 combined with concurrent chemotherapy for treating locally advanced rectal cancer. Conducted in Taiwan, the study involved 20 patients and highlighted a favorable safety profile, with no serious adverse events linked to NBTXR3. Over 70% of participants showed tumor response post-treatment, and 90% underwent surgery, with 17.6% achieving complete pathological response. The study sets the recommended phase II dose at 22% of tumor volume.
Nanobiotix (Paris:NANO, NASDAQ: NBTX), a clinical-stage biotechnology company, has unveiled its ambitious global development plan for NBTXR3, a product candidate aimed at enhancing cancer treatment via radiotherapy. The company aims to complete regulatory requirements for localized head and neck cancer, expand NBTXR3’s applicability to other solid tumors, and establish it as a complementary treatment to immune checkpoint inhibitors. With several ongoing clinical studies and positive FDA designations, Nanobiotix is targeting significant market opportunities as it aims to improve patient outcomes across various cancer types.